Innovative Urine Tests Improve Bladder Cancer Prediction and Treatment Outcomes

Researchers from Stanford University have developed a non-invasive urine test designed to predict treatment outcomes for patients with non-muscle invasive bladder cancer (NMIBC). The study, published in the journal Cell, suggests that this molecular-level assessment can help clinicians determine which patients will benefit from additional immunotherapy and which may be spared from unnecessary intervention.

Bladder cancer originates in the lining of the bladder, the organ responsible for storing urine. It is one of the most common cancers in the United States. Many patients are diagnosed at the NMIBC stage, meaning the tumors are confined to the inner layers of the bladder.

Addressing the Challenges of NMIBC Treatment

Despite early detection, NMIBC is characterized by a high rate of recurrence. For the more than 60,000 patients diagnosed with NMIBC annually, the standard treatment path involves a surgery known as transurethral resection of bladder tumor.

Following surgery, patients exhibiting high-risk features are typically recommended to receive six weekly instillations of bacillus Calmette-Guérin (BCG). BCG is a decades-old immunotherapy administered directly into the bladder to reduce the risk of the cancer returning.

However, the effectiveness of BCG varies significantly between patients. Some individuals may be cured by surgery alone, while others relapse even after receiving the immunotherapy. Until now, medical professionals lacked a reliable method to distinguish between these two groups prior to recurrence.

The Role of the New Urine Test

The new approach developed by investigators from the Stanford Departments of Urology and Radiation Oncology, in collaboration with the Stanford Cancer Institute, utilizes a non-invasive urine test to identify molecular markers. This allows doctors to determine at a molecular level whether a patient is likely to benefit from additional therapy.

When applied to a prospective group of patients who underwent surgery followed by BCG, the refined urine test proved strikingly predictive.

This predictive capability is critical because BCG is associated with significant side effects. There has been a recurrent global shortage in the supply of BCG, making the ability to prioritize the drug for those most likely to benefit a clinical necessity.

Clinical Implications and Precision Oncology

The findings suggest a shift toward personalized treatment decisions in bladder cancer care. By using this test, clinicians may be able to:

• Escalate therapy early for patients identified as being at the highest risk of relapse.
• Spare patients who are unlikely to benefit from BCG from unnecessary and potentially harmful interventions.
• Reduce the time lost waiting for tumors to become visibly apparent during routine monitoring.

The research was primarily supported by funding from the National Cancer Institute. This development aligns with broader trends in precision oncology, including the use of liquid biopsies to improve outcomes for cancer patients.

Broader Context of Urinary Biomarkers

The Stanford study is part of a wider scientific effort to utilize urinary biomarkers for bladder cancer detection and management. Other research, such as a study published in Cancers (Basel) on April 10, 2025, emphasizes that urinary tests can offer affordable and effective alternatives to standard diagnostic methods.

Such biomarkers have the potential to guide new therapeutic strategies and improve early detection. However, researchers note that further proof is still needed to confirm these biomarkers and fully integrate their value into daily clinical routines.